IGF-1

All articles tagged with “IGF-1”

Protocols

Increased Strength

From BPC-157 to MK-677, the new science of peptide-driven body recomposition is challenging the traditional anabolic toolkit.

The era of natural mimicry is here. Peptidomimetics designed to hijack endogenous signaling cascades offer accelerated tissue repair and metabolic correction — but the myostatin paradox, oncologic unknowns, and the regulatory cat-and-mouse game demand clinical caution over marketing hype.

increased strengthBPC-157MK-677AOD9604follistatin+7

PeptidesPeptide

MK-677 (Ibutamoren)

The oral compound that reliably raises GH and IGF-1 to youthful levels, delivers measurable gains in lean mass and sleep architecture, yet consistently failed to translate those biomarker wins into functional outcomes across 30 years of clinical trials.

MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that selectively agonises the ghrelin receptor (GHS-R1a). It increases 24-hour GH secretion by up to 97% and IGF-1 by 60-79%, producing verified gains in fat-free mass and sleep quality. However, the lean mass does not translate to strength, the bone turnover does not translate to density, and insulin resistance is a consistent pharmacological cost.

mk-677

Protocols

Strength & PerformanceOutcome

Increased Strength

From BPC-157 to MK-677, the new science of peptide-driven body recomposition is challenging the traditional anabolic toolkit.

The era of natural mimicry is here. Peptidomimetics designed to hijack endogenous signaling cascades offer accelerated tissue repair and metabolic correction — but the myostatin paradox, oncologic unknowns, and the regulatory cat-and-mouse game demand clinical caution over marketing hype.

increased strengthBPC-157MK-677AOD9604follistatin+7

PeptidesPeptide

MK-677 (Ibutamoren)

The oral compound that reliably raises GH and IGF-1 to youthful levels, delivers measurable gains in lean mass and sleep architecture, yet consistently failed to translate those biomarker wins into functional outcomes across 30 years of clinical trials.

MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that selectively agonises the ghrelin receptor (GHS-R1a). It increases 24-hour GH secretion by up to 97% and IGF-1 by 60-79%, producing verified gains in fat-free mass and sleep quality. However, the lean mass does not translate to strength, the bone turnover does not translate to density, and insulin resistance is a consistent pharmacological cost.

mk-677

ibutamoren

growth-hormone

ghrelin

igf-1

+5